Hims stock surged above a profit-taking zone Friday after facing backlash over its provocative Super Bowl ad that criticized the makers of approved weight-loss drugs. Please watch the video at ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.